Allogene Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Allogene Therapeutics
ALLO Stock  USD 1.80  0.18  11.11%   
Allogene Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Allogene Therapeutics' valuation are provided below:
Gross Profit
-166.5 M
Market Capitalization
364.1 M
Enterprise Value Revenue
3.9 K
Earnings Share
(0.98)
Quarterly Revenue Growth
(1.00)
We have found one hundred twenty available fundamental signals for Allogene Therapeutics, which can be analyzed and compared to other ratios and to its rivals. Self-guided Investors are advised to validate Allogene Therapeutics' prevailing fundamentals against the trend between 2010 and 2026 to make sure the company can sustain itself down the road.

Allogene Therapeutics Total Revenue

24,035

Check Allogene Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Allogene Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 9.2 M, Interest Expense of 197.7 K or Selling General Administrative of 62.4 M, as well as many indicators such as Price To Sales Ratio of 17.8 K, Dividend Yield of 0.0 or PTB Ratio of 0.93. Allogene financial statements analysis is a perfect complement when working with Allogene Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Allogene Stock
Check out the analysis of Allogene Therapeutics Correlation against competitors.
To learn how to invest in Allogene Stock, please use our How to Invest in Allogene Therapeutics guide.

Allogene Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Other Current Liabilities27 M26 M14.7 M
Slightly volatile
Total Current Liabilities45.5 M40.9 M24.6 M
Slightly volatile
Common Stock Total Equity121.7 K163.3 K85.1 K
Slightly volatile
Common Stock Shares Outstanding135.6 M224 M97.3 M
Slightly volatile
Total Liabilities116.2 M145.5 M65.1 M
Slightly volatile
Common Stock148.2 K243.8 K97.2 K
Slightly volatile
Short and Long Term Debt Total78.8 M104.4 M56.5 M
Slightly volatile
Other Liabilities1.3 M1.4 M4.7 M
Slightly volatile
Property Plant And Equipment Net153.1 M151 M94.8 M
Slightly volatile
Other Assets18.4 M19.4 M23 M
Pretty Stable
Long Term Debt27.6 M31 M33.8 M
Slightly volatile
Cash And Short Term Investments433.8 M263.2 M603.7 M
Slightly volatile
Net Receivables2.4 M1.7 M3 M
Slightly volatile
Liabilities And Stockholders Equity661 M493.8 M772.3 M
Pretty Stable
Capital Surpluse1.5 B2.1 B1.3 B
Slightly volatile
Capital Lease Obligations78 M104.4 M56.2 M
Slightly volatile
Other Current Assets8.9 M8.1 M8.1 M
Slightly volatile
Property Plant And Equipment Gross155.5 M222.9 M84.5 M
Slightly volatile
Capital Stock165.3 K243.8 K142.9 K
Slightly volatile
Non Current Liabilities Other6.6 M7 M13 M
Pretty Stable
Intangible Assets129.1 K135.9 K468.1 K
Slightly volatile
Property Plant Equipment127.8 M225.9 M97.7 M
Slightly volatile
Short Term Debt5.2 M8.6 M3.4 M
Slightly volatile
Current Deferred Revenue73.5 K77.4 K25.3 M
Slightly volatile

Allogene Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization9.2 M15.7 M5.4 M
Slightly volatile
Selling General Administrative62.4 M75 M34.8 M
Slightly volatile
Selling And Marketing Expenses17.6 K19.8 K21.6 K
Slightly volatile
Other Operating Expenses259.1 M314.2 M144.6 M
Slightly volatile
Research Development213.5 M221.1 M179.5 M
Slightly volatile
Total Operating Expenses259.1 M314.2 M144.6 M
Slightly volatile
Net Interest Income24.1 M23 M8 M
Slightly volatile
Interest Income24.3 M23.2 M9.8 M
Slightly volatile
Reconciled Depreciation10.4 M15.7 M6.1 M
Slightly volatile

Allogene Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Net Borrowings93.5 M105.2 M114.8 M
Slightly volatile
Depreciation9.3 M15.7 M5.9 M
Slightly volatile
Capital Expenditures593.4 K624.6 K11.3 M
Very volatile
Total Cash From Financing Activities99.8 M105 M474.4 M
Slightly volatile
Change To Netincome76.9 M84.7 M116.4 M
Slightly volatile
Sale Purchase Of Stock1.3 M1.4 M347.4 M
Slightly volatile
Stock Based Compensation64.7 M59.5 M40.3 M
Slightly volatile
Other Cashflows From Financing Activities1.9 M2.1 M507.3 M
Slightly volatile
Other Non Cash Items21.5 M14.6 M76.6 M
Slightly volatile
Issuance Of Capital Stock185.3 M100.8 M414.8 M
Slightly volatile
End Period Cash Flow102.9 M77 M107.7 M
Pretty Stable

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio17.8 K17 K3.8 K
Slightly volatile
Days Sales Outstanding15.2 K28.4 K9.8 K
Slightly volatile
Stock Based Compensation To Revenue2.2 K2.1 K466
Slightly volatile
Capex To Depreciation0.05560.05852.4052
Pretty Stable
EV To Sales18.5 K17.6 K4 K
Slightly volatile
Payables Turnover0.710.930.7236
Slightly volatile
Sales General And Administrative To Revenue2.8 K2.7 K571
Slightly volatile
Research And Ddevelopement To Revenue8.3 K7.9 K1.7 K
Slightly volatile
Capex To Revenue16.1928.397.5067
Slightly volatile
Cash Per Share1.641.735.8367
Slightly volatile
Days Payables Outstanding497408551
Slightly volatile
Income Quality0.490.70.4224
Slightly volatile
Intangibles To Total Assets2.0E-42.0E-46.0E-4
Slightly volatile
Current Ratio12.879.8213.6288
Slightly volatile
Receivables Turnover0.01260.01330.0482
Slightly volatile
Debt To Equity0.20.190.0939
Slightly volatile
Capex Per Share0.00390.00410.0936
Very volatile
Revenue Per Share1.0E-41.0E-40.5931
Slightly volatile
Interest Debt Per Share0.420.46680.4661
Slightly volatile
Debt To Assets0.07640.150.0736
Slightly volatile
Operating Cycle15.2 K28.4 K9.8 K
Slightly volatile
Days Of Payables Outstanding497408551
Slightly volatile
Ebt Per Ebit1.091.081.0527
Slightly volatile
Company Equity Multiplier0.951.171.1309
Slightly volatile
Total Debt To Capitalization0.080.160.0779
Slightly volatile
Debt Equity Ratio0.20.190.0939
Slightly volatile
Quick Ratio14.279.8218.419
Slightly volatile
Net Income Per E B T0.620.90.5408
Slightly volatile
Cash Ratio2.312.4414.2057
Slightly volatile
Days Of Sales Outstanding15.2 K28.4 K9.8 K
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.291.151.1285
Pretty Stable
Fixed Asset Turnover2.0E-42.0E-40.445
Slightly volatile
Debt Ratio0.07640.150.0736
Slightly volatile
Price Sales Ratio17.8 K17 K3.8 K
Slightly volatile
Asset Turnover0.00.00.0767
Slightly volatile

Allogene Fundamental Market Drivers

Allogene Upcoming Events

27th of February 2024
Upcoming Quarterly Report
View
1st of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
27th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Allogene Therapeutics Financial Statements

Allogene Therapeutics investors utilize fundamental indicators, such as revenue or net income, to predict how Allogene Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue77.4 K73.5 K
Total Revenue25.3 K24 K
Cost Of Revenue15.7 M10.4 M
Stock Based Compensation To Revenue2.1 K2.2 K
Sales General And Administrative To Revenue2.7 K2.8 K
Research And Ddevelopement To Revenue7.9 K8.3 K
Capex To Revenue 28.39  16.19 
Ebit Per Revenue-14.3 K-13.6 K

Pair Trading with Allogene Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Allogene Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Allogene Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Allogene Stock

  0.64GXEA Galapagos NVPairCorr
  0.678VP1 AVRICORE HEALTH INCPairCorr

Moving against Allogene Stock

  0.79OSE OSE Pharma SAPairCorr
  0.71RAC Race OncologyPairCorr
  0.62DRMA Dermata TherapeuticsPairCorr
  0.48VCEL Vericel Corp OrdPairCorr
  0.45CDIOW Cardio DiagnosticsPairCorr
The ability to find closely correlated positions to Allogene Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Allogene Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Allogene Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Allogene Therapeutics to buy it.
The correlation of Allogene Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Allogene Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Allogene Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Allogene Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Allogene Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Allogene Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Allogene Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Allogene Therapeutics Stock:
How To Invest In Allogene
Details
Is Allogene Stock a good investment?
Details
What is Allogene Therapeutics' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Allogene Therapeutics Correlation against competitors.
To learn how to invest in Allogene Stock, please use our How to Invest in Allogene Therapeutics guide.
You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Will Biotechnology sector continue expanding? Could Allogene diversify its offerings? Factors like these will boost the valuation of Allogene Therapeutics. If investors know Allogene will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Allogene Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share
(0.98)
Quarterly Revenue Growth
(1.00)
Return On Assets
(0.27)
Return On Equity
(0.54)
The market value of Allogene Therapeutics is measured differently than its book value, which is the value of Allogene that is recorded on the company's balance sheet. Investors also form their own opinion of Allogene Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Allogene Therapeutics' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Allogene Therapeutics' market value can be influenced by many factors that don't directly affect Allogene Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Understanding that Allogene Therapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Allogene Therapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, Allogene Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY